Bleeding score was found to be lowest in megestrol group
(4.9 ± 1.1) compared to other two groups (Figure 3).
Patient characteristics of patients with and without
endometrial hyperplasia were compared within megestrol
group as shown in Table 2. Endometrial hyperplasia was
seen in 52% of patients within group III.Those patients with
endometrial hyperplasia had a significantly higher mean
BMI (40.8 ± 3.1) than those without (31.7 ± 1.8, P , 0.05).
There was no significant difference in either the number of
days bleeding prior to or after treatment between these two
subgroups. There was also no significant difference in the
bleeding score between them